CD274 and colorectal carcinoma: CRC cases with MSI+ phenotype are predicted to respond to immune checkpoint inhibition against PD1 or PD‐L1 and several studies have shown the efficacy of a pembrolizumab treatment in MSI+ CRC.5, 6